Letters, Testimony & Comments

BIO submits letters, testimony, and comments to government and regulatory bodies throughout the United States and around the world.

Featured Letters, Testimony, & Comments

ohn’s One-Year Anniversary Letter to BIO…

Dear Colleagues,This month marks my one-year anniversary as BIO’s CEO. Like most of us in biotech, this post has been a labor of love. At no time in my 25-year career in this industry have I ever witnessed such awe-inspiring science. Today, we…

Learn more

BIO Comments on Office of Management and Budget …

Re: BIO Comments on Office of Management and Budget (OMB) Statistical Policy Directive No. 8 North American Industry Classification System (NAICS)-Request forComments on Possible Revisions for 2027 (USBC–2024–0032)Dear Ms. Orvis,The Biotechnology…

Learn more

BIO Letter to HRSA on 340B Rebate Model

Under the 340B program, participating manufacturers must offer 340B pricing on their covered outpatient drugs by covered entities, as a condition of having those drugs federally payable under Medicare Part B and Medicaid. Critically, Congress…

Learn more

BIO letter in support of H.R. 5418

March 10, 2016

To establish a pilot program for educating district court judges on patent related issues.

Cures Acceleration Network: Legislative Text

March 10, 2016

The Cures Acceleration Network, passed in the recently enacted healthcare reform bill, will provide funding to public and private entities to bridge the gap between basic research and cures for patients.

Small Business Early Stage Investment Program: Legislative Text

March 10, 2016

The Small Business Early Stage Investment Program would provide matching funds for investment companies who invest in small, high tech companies, including biotech firm.

BIO’s comments to the USDA on the biomass crop assistance program enacted by the 2008 Farm Bill

March 10, 2016

Comments are regarding conservation and stewardship requirements, matching payments, establishment costs and annual payments, disclosure of competitively sensitive information, invasiveness determination and review, consistency with existing FSA…

Presentation: "Global Health Challenges: How Industry is Addressing Global Health", presented at the University of Virginia in June 2008

March 10, 2016

Global Health Challenges: How Industry is Addressing Global Health

Diran Makinde, Network Director, NEPAD Biosciences, West Africa Biosciences Network (WABNet), Senegal

March 10, 2016

Government's role in developing solutions for diseases that disproportionately affect developing countries

Mark Rohrbaugh, Director, Office of Technology Transfer, National Institutes of Health (NIH)

March 10, 2016

Mark Rohrbaugh, Director, Office of Technology Transfer, National Institutes of Health (NIH), US Department of Health & Human Services, USA

Ted Roumel, Vice President for Research Innovation & Commercialization at the University of Maryland Biotechnology Institute, USA

March 10, 2016

Innovation And The Global Research Enterprise WORLD HEALTH ORGANIZATION GENEVA—NOVEMBER 2007 THEODORE J. ROUMEL VICE PRESIDENT for RESEARCH, INNOVATION AND COMMERCIALIZATION UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE

Eileen Yen, former Director, Sarawak Biodiversity Centre, Malaysia

March 10, 2016

The Patent Reform Act of 2007 - Coalition Letter

March 10, 2016

More than 430 organizations representing American innovation in a wide range of industries in all 50 states wrote Senate leaders to express continued concern with S. 1145.